Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 1, Janvier 2012
Page(s) 82 - 88
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2012281021
Publié en ligne 27 janvier 2012
  1. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006 2006. [Google Scholar]
  2. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002 ; 24 : 1720–1740. [CrossRef] [PubMed] [Google Scholar]
  3. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005 ; 36 : 3–10. [CrossRef] [PubMed] [Google Scholar]
  4. Bertolotto A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 2004 ; 17 : 241–246. [CrossRef] [PubMed] [Google Scholar]
  5. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010 ; 38 : 82–89. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed] [Google Scholar]
  6. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002 ; 346 : 469–475. [CrossRef] [PubMed] [Google Scholar]
  7. Hermeling S, Jiskoot W, Crommelin D, et al. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm Res 2005 ; 22 : 847–851. [CrossRef] [PubMed] [Google Scholar]
  8. Reipert BM, Steinitz KN, van Helden PM, et al. Opportunities and limitations of mouse models humanized for HLA class II antigens. J Thromb Haemost 2009 ; 7 (suppl 1) : 92–97. [CrossRef] [PubMed] [Google Scholar]
  9. Becker PD, Legrand N, van Geelen CM, et al. Generation of human antigen-specific monoclonal IgM antibodies using vaccinated “human immune system” mice. PLoS One 2010 ; 5. [Google Scholar]
  10. Jacquemin M, Vantomme V, Buhot C, et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003 ; 101 : 1351–1358. [CrossRef] [PubMed] [Google Scholar]
  11. Bray GL, Kroner BL, Arkin S, et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-center hemophilia cohort study. Am J Hematol 1993 ; 42 : 375–379. [CrossRef] [PubMed] [Google Scholar]
  12. Yeung VP, Chang J, Miller J, et al. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 2004 ; 172 : 6658–6665. [PubMed] [Google Scholar]
  13. Wang P, Sidney J, Dow C, et al. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008 ; 4 : e1000048. [CrossRef] [PubMed] [Google Scholar]
  14. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998 ; 160 : 3363–3373. [PubMed] [Google Scholar]
  15. Castelli FA, Leleu M, Pouvelle-Moratille S, et al. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and core proteins. Eur J Immunol 2007 ; 37 : 1513–1523. [CrossRef] [PubMed] [Google Scholar]
  16. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010 ; 116 : 4542–4545. [CrossRef] [PubMed] [Google Scholar]
  17. Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. Faseb J 2011 ; 25 : 2040–2048. [CrossRef] [PubMed] [Google Scholar]
  18. Moon JJ, Chu HH, Pepper M, et al. Naive CD4+ T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007 ; 27 : 203–213. [CrossRef] [PubMed] [Google Scholar]
  19. Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med 2009 ; 206 : 1525–1534. [CrossRef] [PubMed] [Google Scholar]
  20. Jenkins MK, Chu HH, McLachlan JB, Moon JJ. On the composition of the preimmune repertoire of T cells specific for peptide-major histocompatibility complex ligands. Annu Rev Immunol 2010 ; 28 : 275–294. [CrossRef] [PubMed] [Google Scholar]
  21. Ohashi PS, Oehen S, Buerki K, et al. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991 ; 65 : 305–317. [CrossRef] [PubMed] [Google Scholar]
  22. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum 2005 ; 52 : 2740–2750. [CrossRef] [PubMed] [Google Scholar]
  23. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003 ; 348 : 601–608. [CrossRef] [PubMed] [Google Scholar]
  24. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001 ; 19 : 843–850. [PubMed] [Google Scholar]
  25. Van Walle I, Gansemans Y, Parren PW, et al. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007 ; 7 : 405–418. [CrossRef] [PubMed] [Google Scholar]
  26. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 ; 66 : 921–926. [CrossRef] [PubMed] [Google Scholar]
  27. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007 ; 25 : 40–46. [PubMed] [Google Scholar]
  28. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004 ; 50 : 2580–2589. [CrossRef] [PubMed] [Google Scholar]
  29. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2010 ; 69 : 409–412. [CrossRef] [PubMed] [Google Scholar]
  30. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: Still an unsolved mystery. J Immunotoxicol 2006 ; 3 : 123–130. [CrossRef] [PubMed] [Google Scholar]
  31. Stas P, Lasters I. Immunogénicité de protéines d’intérêt thérapeutique : les anticorps monoclonaux thérapeutiques. Med Sci (Paris) 2009 ; 25 : 1070–1077. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Cogné M, Duchez S, Pascal V. Transgenèse animale et humanisation des anticorps : des souris pour des hommes. Med Sci (Paris) 2009 ; 25 : 1149–1154. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  33. Sibilia J. Protéine de fusion ou anticorps monoclonal : quel biomédicament choisir dans une maladie inflammatoire ? Med Sci (Paris) 2009 ; 25 : 1033–1038. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Casadevall N, Mayeux P. Anticorps anti-érythropoïétine chez des patients insuffisants rénaux traités par l’hormone recombinante. Med Sci (Paris) 2002 ; 18 : 542–543. [CrossRef] [EDP Sciences] [Google Scholar]
  35. Cachat A, Duc Dodon M, Gazzolo L, Rigal D, Villaudy J. Les souris ne sont pas des hommes, et pourtant… Ce que les souris humanisées nous apprennent sur les maladies infectieuses. Med Sci (Paris) 2012 ; 28 : 63–68. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  36. Abès R, Dutertre CA, Teillaud JL. Les anticorps : mieux les connaître pour mieux s’en servir. Med Sci (Paris) 2009 ; 25 : 1011–1019. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.